Saturday 17 October 2026
Export LFMD’s income statement to Excel — free account
LifeMD, Inc.
LFMD Healthcare Health Information Services
LifeMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $194.1 million, up 25.3% from fiscal 2024. In the quarter to June 2026, revenue fell 3.55%, EPS fell 166.7% and free cash flow fell 247.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
2.34
0.12
−4.88%
Follow LFMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 72.20 | 13.12 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.03 | 0.88 | 0.79 | 1.88 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 101.82 | |
P/Operating CF |
(28.50) | 384.35 | (46.91) | (2,130.84) | |
P/B ratio |
24.77 | 11.36 | 6.65 | 93.07 | |
Price to Tangible BV |
25.41 | 11.54 | 6.72 | 173.20 | |
EV/Sales |
0.98 | 0.79 | 0.68 | 1.83 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(18.94) | 26.85 | 16.01 | 24.15 | |
EV/FCF |
(10.27) | (38.76) | (106.73) | 99.12 | |
Quick Ratio |
0.78 | 0.89 | 1.11 | 0.58 | |
Current Ratio |
0.90 | 1.04 | 1.25 | 0.73 | |
Net Debt/EBITDA |
4.94 | 4.97 | 11.03 | (7.77) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
2.87 | 2.69 | 2.65 | 2.41 | |
Operating CF/Net income |
0.88 | (0.05) | (0.17) | 0.03 | |
Capex/Depreciation |
(0.80) | (1.03) | (0.55) | (1.06) | |
Interest Coverage |
— | 158.04 | (3.42) | (7.50) | |
Research and Development Expense of Revenue |
3.79% | 3.58% | 2.41% | 4.73% | |
Selling, General and Administrative Expense of Revenue |
88.16% | 89.81% | 72.83% | 76.55% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.02 | |
Share Based Compensation of Revenue |
1.67% | 2.89% | 7.81% | 5.31% | |
Graham Net Nets |
(0.05) | (0.02) | 0.03 | (0.07) | |
Graham Number |
0.00 | 0.60 | 1.73 | 0.00 | |
Earnings Yield |
(1.21%) | 1.39% | 7.62% | (2.50%) | |
Free Cash Flow Yield |
(9.26%) | (2.29%) | (0.81%) | 0.98% | |
Revenue per Share |
0.99 | 1.06 | 0.75 | 1.30 | |
Operating CF per Share |
(0.14) | 0.01 | (0.07) | 0.00 | |
Capex per Share |
(0.03) | (0.04) | 0.01 | (0.12) | |
Free Cash Flow per Share |
(0.18) | (0.03) | (0.06) | (0.12) | |
Cash per Share |
0.53 | 0.73 | 0.82 | 0.52 | |
Shareholders Equity per Share |
0.17 | 0.32 | 0.51 | 0.07 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.17 | 0.32 | 0.51 | 0.07 | |
Free Cash Flow |
(8.56) | (1.61) | (2.64) | (5.47) | |
Working Capital |
(4.52) | 2.11 | 10.26 | (15.58) | |
Capital Expenditures |
(1.63) | (2.06) | 0.64 | (5.32) | |
Net Current Asset Value |
(9.84) | (3.39) | 4.58 | (21.53) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.04 | (0.02) | 0.09 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.29 | 10.02 | 9.88 | 7.65 | |
Average Payables |
21.22 | 18.67 | 12.53 | 17.71 | |
Average Inventory |
3.10 | 3.07 | 2.79 | 3.04 | |
Average Assets |
66.73 | 71.87 | 73.25 | 69.27 | |
Average Common Equity |
4.17 | 7.32 | 7.80 | (1.29) |
Columns are period end dates